Clinical trial
CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse
NCT00003131 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00003131 |
|---|---|
| Title | CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse |
| Official title | A Study of the Efficacy and Safety of CMA-676 as Single Agent Treatment of Patients With Acute Myeloid Leukemia (AML) in First Relapse |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | chemotherapy, gemtuzumab ozogamicin |
| Enrollment | 55 |
| Start date | Feb 1, 1997 |
| Primary completion | Feb 1, 2002 |
| Completion | Feb 1, 2002 |
| First posted | Aug 24, 2004 |
| Last update posted | Aug 22, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: